赖戈奈截至2021年6月30日的现金职位

赖戈奈截至2021年6月30日的现金职位150.150.Lysogene
  • 现金和现金等价物为1500万欧元1截至2021年6月30日

巴黎,法国 - 7月23日2021年在08:00 AM CET - Lysogene(fr0013233475 - lys),今天,达到中枢神经系亚搏全站app下载统(CNS)疾病的第3阶段基因治疗平台公司报告其截至2021年6月30日的现金职位。

截至2021年6月30日,现金和现金等价物总计1500万欧元1(截至2021年3月31日的额外增加20.0百万欧元)。2021年7月28日,赖戈氏将为280万美元(约440万欧元2)在与工业伙伴的商业纠纷之后,最高估计风险的商业纠纷是5000万美元(约420万欧元2)。2020年财务报表中录制了120万欧元的剩余条款。

StéphaneDurantdes Aulnois,Lysogene的首席财务官评论:“公司实施的强大财务纪律帮助我们在上半年保护了现金,并主要预测了争议的结果。因此,我们的财务知名度仍然持续到2022年上半年,我们正在积极评估不同的融资选择来扩展它。“

1未经审计的图
22021年7月19日以欧元/美元汇率为1.1766

关于溶酶

Lysogene是一种基因治亚搏全站app下载疗公司,专注于治疗中枢神经系统(CNS)的孤儿疾病。该公司建立了一种独特的能力,使得能够将基因疗法传递给CNS以治疗CNS的溶酶体疾病和其他遗传疾病。与Sarepta Therapeutics,Inc.合作的MPS IIIA中的2/3阶段临床试验正在进行中。在GM1神经节病菌中的适应性临床试验正在进行中。亚博登录首页根据溶酶和Sarepta Therapeutics,Inc。之间签署的协议,Sarepta Therapeutics,Inc。将在美国和欧洲以外的市场举办Lys-Saf302的独家商业权利;和溶酶将在欧洲维持Lys-Saf302的商业专用性。Lysogene还与Satt Concectus进行了独家全球许可协议,用于治疗脆弱的X综合征的基因治疗候选者,该遗传疾病与自闭症有关。亚搏全站app下载www.astridbowlby.com.

前瞻性陈述

本新闻稿可能包含某些前瞻性陈述,特别是本公司对其临床试验和现金跑道的进展。Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, theseforward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

此新闻稿已准备法语和英语。如果两者之间存在任何差异
文本,法语版本应该取代。

联系人
Stéphanedurant des aulnois
首席财务官
stephane.durant-des-aulnois@lysogene.com
+33 1 41 43 03 99

Lysogene COVID-19更新

取得联系

如果你需要更多的帮助,请随时联系我们。

    回到顶部